Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(2.29)
# 2,585
Out of 4,732 analysts
489
Total ratings
37.74%
Success rate
-0.48%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Buy | $25 | $2.74 | +812.41% | 23 | Jan 17, 2025 | |
| OTLK Outlook Therapeutics | Reiterates: Buy | $30 | $2.23 | +1,245.29% | 15 | Jan 17, 2025 | |
| ARGX argenx SE | Reiterates: Buy | $670 → $717 | $640.52 | +11.94% | 33 | Jan 14, 2025 | |
| APLS Apellis Pharmaceuticals | Reiterates: Buy | $57 | $29.94 | +90.41% | 24 | Jan 14, 2025 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Buy | $81 | $37.35 | +116.87% | 23 | Jan 13, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | $19 | $12.68 | +49.84% | 2 | Jan 13, 2025 | |
| NMRA Neumora Therapeutics | Reiterates: Buy | $30 | $2.05 | +1,363.41% | 4 | Jan 3, 2025 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $34 | $18.13 | +87.53% | 15 | Dec 17, 2024 | |
| BHVN Biohaven | Reiterates: Buy | $59 | $37.59 | +56.96% | 13 | Dec 17, 2024 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $3.34 | +259.28% | 16 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $38.52 | +37.59% | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $120 | $70.54 | +70.12% | 21 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $36.82 | +35.80% | 25 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $58.25 | +102.59% | 13 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.39 | +403.60% | 22 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 | $7.08 | +97.74% | 21 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.28 | +448.78% | 11 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.54 | +270.44% | 19 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $11.15 | +61.43% | 16 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6.6 | $3.68 | +79.35% | 19 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $4.87 | +187.47% | 14 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 | $23.86 | +113.75% | 19 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $10.51 | +156.90% | 23 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $4.11 | +94.65% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.23 | +124.22% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $37 | $29.47 | +25.55% | 22 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.15 | +3,146.75% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $8.58 | +74.83% | 13 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.06 | +843.40% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $10 | $12.74 | -21.51% | 7 | Dec 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $198.11 | -8.13% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $3.66 | +412.30% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $20.82 | -13.54% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $21.92 | -63.50% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $22.36 | +132.56% | 2 | Jun 11, 2019 |
Cabaletta Bio
Jan 17, 2025
Reiterates: Buy
Price Target: $25
Current: $2.74
Upside: +812.41%
Outlook Therapeutics
Jan 17, 2025
Reiterates: Buy
Price Target: $30
Current: $2.23
Upside: +1,245.29%
argenx SE
Jan 14, 2025
Reiterates: Buy
Price Target: $670 → $717
Current: $640.52
Upside: +11.94%
Apellis Pharmaceuticals
Jan 14, 2025
Reiterates: Buy
Price Target: $57
Current: $29.94
Upside: +90.41%
Crinetics Pharmaceuticals
Jan 13, 2025
Reiterates: Buy
Price Target: $81
Current: $37.35
Upside: +116.87%
Arcutis Biotherapeutics
Jan 13, 2025
Reiterates: Buy
Price Target: $19
Current: $12.68
Upside: +49.84%
Neumora Therapeutics
Jan 3, 2025
Reiterates: Buy
Price Target: $30
Current: $2.05
Upside: +1,363.41%
Viridian Therapeutics
Dec 17, 2024
Reiterates: Buy
Price Target: $34
Current: $18.13
Upside: +87.53%
Biohaven
Dec 17, 2024
Reiterates: Buy
Price Target: $59
Current: $37.59
Upside: +56.96%
Daré Bioscience
Dec 17, 2024
Reiterates: Buy
Price Target: $12
Current: $3.34
Upside: +259.28%
Dec 12, 2024
Reiterates: Buy
Price Target: $53
Current: $38.52
Upside: +37.59%
Dec 12, 2024
Reiterates: Buy
Price Target: $120
Current: $70.54
Upside: +70.12%
Dec 10, 2024
Reiterates: Buy
Price Target: $50
Current: $36.82
Upside: +35.80%
Dec 9, 2024
Reiterates: Buy
Price Target: $118
Current: $58.25
Upside: +102.59%
Dec 4, 2024
Reiterates: Buy
Price Target: $7
Current: $1.39
Upside: +403.60%
Nov 20, 2024
Reiterates: Neutral
Price Target: $14
Current: $7.08
Upside: +97.74%
Nov 14, 2024
Reiterates: Buy
Price Target: $18
Current: $3.28
Upside: +448.78%
Nov 14, 2024
Reiterates: Neutral
Price Target: $2
Current: $0.54
Upside: +270.44%
Nov 13, 2024
Reiterates: Buy
Price Target: $18
Current: $11.15
Upside: +61.43%
Nov 8, 2024
Reiterates: Neutral
Price Target: $6.6
Current: $3.68
Upside: +79.35%
Nov 8, 2024
Reiterates: Buy
Price Target: $14
Current: $4.87
Upside: +187.47%
Nov 8, 2024
Reiterates: Buy
Price Target: $51
Current: $23.86
Upside: +113.75%
Nov 7, 2024
Reiterates: Buy
Price Target: $27
Current: $10.51
Upside: +156.90%
Nov 7, 2024
Reiterates: Buy
Price Target: $8
Current: $4.11
Upside: +94.65%
Nov 6, 2024
Reiterates: Neutral
Price Target: $5
Current: $2.23
Upside: +124.22%
Oct 25, 2024
Reiterates: Neutral
Price Target: $37
Current: $29.47
Upside: +25.55%
Oct 1, 2024
Reiterates: Buy
Price Target: $5
Current: $0.15
Upside: +3,146.75%
Sep 16, 2024
Reiterates: Buy
Price Target: $15
Current: $8.58
Upside: +74.83%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.06
Upside: +843.40%
Dec 9, 2021
Maintains: Neutral
Price Target: $23 → $10
Current: $12.74
Upside: -21.51%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $198.11
Upside: -8.13%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $3.66
Upside: +412.30%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $20.82
Upside: -13.54%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $21.92
Upside: -63.50%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $22.36
Upside: +132.56%